Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

269.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
From Natera, Inc.
Via Business Wire
Natera (NTRA) Q1 Revenue Beat Overshadowed by EPS Miss and Operating Losses ↗
Via Chartmill
News headline image
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
From Natera, Inc.
Via Business Wire
News headline image
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.7% in the morning session after the company announced its Signatera test rece... 
Via StockStory
Topics Artificial Intelligence
News headline image
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
From Natera, Inc.
Via Business Wire
News headline image
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
From Natera, Inc.
Via Business Wire
News headline image
1 Healthcare Stock for Long-Term Investors and 2 We Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
1 Cash-Heavy Stock on Our Buy List and 2 We Avoid
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
Topics Retirement
News headline image
2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia) ↗
The famous hedge fund manager seems to have found a hidden gem outside of the market's most popular stock picks. 
Via The Motley Fool
News headline image
Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
From Natera, Inc.
Via Business Wire
News headline image
NWI Management Dumps 42,700 MercadoLibre Shares Worth $82.4 Million ↗
MercadoLibre delivers e-commerce and fintech solutions across Latin America, leveraging an integrated digital ecosystem for regional growth. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
From Natera, Inc.
Via Business Wire
News headline image
Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
From Natera, Inc.
Via Business Wire
News headline image
EXPAND Trial of Natera’s Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
From Natera, Inc.
Via Business Wire
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call
Natera’s first quarter was marked by robust top-line growth and higher-than-expected sales volumes, but the market responded negatively due to a wider-than-a... 
Via StockStory
Topics Earnings
News headline image
Why Natera (NTRA) Shares Are Plunging Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). fell 12.2% in the afternoon session after the company reported mixed first-quarter 202... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Natera Q1 Earnings Call Highlights ↗
Natera (NASDAQ:NTRA) reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief... 
Via MarketBeat
Topics Earnings
News headline image
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 38.8% year on year to $696.... 
Via StockStory
News headline image
Natera NTRA Q1 2026 Earnings Call Transcript ↗
Natera NTRA Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top Estimates
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2026, with sales up 38.8% year on year to $696.6 million. Its GA... 
Via StockStory
News headline image
Natera Reports First Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.